This page shows the latest Illumina news and features for those working in and with pharma, biotech and healthcare.
That includes a recent alliance with Illumina on genomic testing for cancer diagnostics, which aims to define a patient’s unique cancer using the genomics systems and leverage the resulting genomic
Will leverage genomics system to match optimal cancer treatment. Roche and Illumina have announced a 15-year alliance for genomics testing, aimed at transforming cancer diagnostics. . ... Roche will collaborate with Illumina to complement its
One of these includes Genomics England, with Illumina providing the genome sequencing systems for the 100, 000 Genome Project. ... Illumina announced its plans to acquire PacBio in No. vember last year, for $1.2bn in an all-cash transaction.
Boost for UK's golden triangle biotech region. Illumina has set up its first hub for genomics start-up funding outside the US, and has chosen Cambridge in the UK for ... harness the rapid and affordable next-generation sequencing technology pioneered by
Grail is a spin-out of genome sequencing giant Illumina, and is leveraging the whole genome sequencing (WGS) power of its parent company with the goal of revolutionising cancer diagnostics.
To try to address the diagnostic issue, Loxo formed a partnership earlier this year with Illumina to develop a simple test – called TruSight Tumour 170 – that will use sequencing to identify
More from news
Approximately 10 fully matching, plus 13 partially matching documents found.
centre run by Illumina, and an automated analytics platform to return whole genome analyses to the NHS.
IBM Watson Health/ Illumina. Partnership to integrate Watson for Genomics into Illumina's BaseSpace Sequence Hub and tumour sequencing process to expand access to genomic data.
Speakers. Dan Coffin, Global Head of Illuminas Health. Dan now heads up the global pharmaceutical arm of Illuminas and brings an interesting mix of experiences having worked agency side at Isis
Roche, rumoured to be interested in Alexion, may still be smarting from the battle to try and take over Illumina last year.
So where could Roche go next? With its unsuccessful takeover bid for Illumina, it could be a move into genetic sequencing to augment their oncology capability and more besides.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
John Thompson brings experience from IBM and Microsoft. San Diego, US-based Illumina has appointed John Thompson to its board of directors. ... Francis de Souza, president and chief executive of Illumina, said: “John brings a great breadth of knowledge
He has spent 18 years in varous positions in the life sciences consulting industry, including roles at, Bionest Partners, IMS Management Consulting, and Illumina Inc.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
To bring home the importance of this diagnostic technology, the CEO of Illumina (a top DNA sequencing firm) believes this technology will become the “ stethoscope for the next 200 years.” A
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...